Dr. Reyes is a biophysicist and entrepreneur with a passion for creating solutions to improve our health, environment and economic sustainability. Dr. Reyes has founded two companies focused on developing therapeutics to address serious medical needs as well as a tech company focused on connecting people to socially conscious commerce solutions. His first company Eclipse Therapeutics, a cancer stem cell focused start-up, resulted in a successful acquisition in 18 months. Dr. Reyes has a Ph.D. in Biophysics at the University of California, San Francisco and B.A. in Molecular and Cell Biology, Biophysics from the University of California, Berkeley. Dr. Reyes was a postdoctoral fellow at The Scripps Research Institute. Dr. Reyes has received honors from the National Science Foundation, the Ford Foundation and was a McNair Scholar.
Developing The Next Generation Of Living Medicines
Bloom Science is developing genetically optimized living medicines that target diseases in neurology, immunology and oncology. Our unique approach elucidates connections between clinical outcomes, the microbiome, and critical disease pathways. We then use genetic tools to engineer superior biopharmaceutical properties in our microbiota therapeutics.
Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.
Microbiome and Cancer
Jennifer Wargo, MD Anderon
Sandrine Miller-Montgomery, UCSD
The Gut/Brain Microbiome
Mary Conrad, Axial Biotherapeutics
Chris Reyes, Bloom Science
The Role of the Human Gut Microbiome on Various Diseases
Colleen Cutcliffe, Pendulum Therapeutics
Tor Savidge, Baylor College of Medicine
Nikole Kimes, Siolta Therapeutics
Pharma Drug Development
Karim Dabbagh, Second Genome
Ethan Grant, Gilead
Kiran Krishnan, Microbiome Labs
Scott Jackson, NIST